Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696589 | 0.79 | MMP13 (0.56) | MMP13LMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL6700976 | 0.78 | MMP13 (0.57) | MMP13LMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL6297353 | 0.78 | MMP13 (1.00) | MMP13SMN1; SMN2L3MBTL1GRK2 | |
| SCHEMBL6302837 | 0.77 | MMP13 (0.73) | MMP13SMN1; SMN2L3MBTL1GRK2 | |
| SCHEMBL6700130 | 0.77 | LMNA (0.52) | MMP13LMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL6703229 | 0.72 | MMP13 (0.51) | MMP13LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6704202 | 0.72 | MMP13 (0.57) | MMP13LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6703263 | 0.71 | MMP13 (0.65) | MMP13SMN1; SMN2 | |
| SCHEMBL6704886 | 0.71 | MMP13 (0.56) | MMP13LMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL6822798 | 0.71 | MMP13 (0.56) | MMP13LMNASMN1; SMN2L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885LMNA 2847/4885SMN1; SMN2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.